1.Cohen, ML. Epidemiology of drug resistance: implications for a post-antimicrobial era. Science 1992; 257:1050–1055.
2.Holmberg, SD, Solomon, SL, Blake, PA. Health and economic impacts of antimicrobial resistance. Rev Infect Dis 1987; 9:1065–1078.
3.Leibovici, L, Shraga, I, Drucker, M, Konigsberger, H, Samra, Z, Pitlik, SD. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998; 244:379–386.
4.Weinstein, MP, Towns, ML, Quartey, SM, et al. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis 1997; 24:584–602.
5.Ibrahim, EH, Sherman, G, Ward, S, Fraser, VJ, Kollef, MH. The influence of inadequate antimicrobial treatment of bloodstream infection on patient outcome in the ICU setting. Chest 2000; 118:146–155.
6.Alvarez-Lerna, F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit: ICU-Acquired Pneumonia Study Group. Intensive Care Med 1996; 22:387–394.
7.National Committee for Clinical Laboratory Standards (NCCLS). Abbreviated Identification of Bacteria and Yeast; Approved Guideline. Wayne, PA: NCCLS; 2002. NCCLS document M35-A.
8.National Committee for Clinical Laboratory Standards (NCCLS). Performance Standards for Antimicrobial Susceptibility Testing. Wayne, PA: NCCLS; 2001. NCCLS approved standard M100-S11.
9.Ernst, EJ, Diekema, DJ, BootsMiller, BJ, et al. Are United States hospitals following national guideline for the analysis and presentation of cumulative antimicrobial susceptibility data? Diagn Microbiol Infect Dis 2004; 49:141–145.
10.Takigawa, K, Fujita, J, Negayama, K, et al. Comparing antimicrobial activity against resistant Pseudomonas aeruginosa using an index for the absence of cross-resistance. J Antimicrob Chemother 1995; 35:425–427.
11.Bouza, E, Garcia-Garrote, F, Cercenado, E, Martin, M, Diaz, MS, for the Spanish Pseudomonas aeruginosa Study Group. Pseudomonas aeruginosa; a survey of resistance in 136 hospitals in Spain. Antimicrob Agents Chemother 1999; 43:981–982.
12.Bonfiglio, G, Carciotto, V, Russo, G, et al. Antibiotic resistance in Pseudomonas aeruginosa: an Italian study. J Antimicrob Chemother 1998; 41:307–310.
13.Friedland, I, Stinson, L, Ikaiddi, M, Harm, S, Woods, GL. Phenotypic antimicrobial resistance patterns in Pseudomonas aeruginosa and Acinetobacter: results of a multicenter intensive care unit surveillance study, 1995-2000. Diagn Microbiol Infect Dis 2003; 45:245–250.
14.Young, LS. Sepsis syndrome. In: Mandell, GL, Bennett, JE, Dolin, R, eds. Principles and Practice of Infectious Diseases. 5th ed. Philadelphia, PA: Churchill Livingstone; 2000:806–819.
15.Flamm, RK, Weaver, MK, Thornsberry, C, Jones, ME, Karlowsky, JA, Sahm, DF. Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates in clinical laboratories in the United States from 1999 to 2002. Antimicrob Agents Chemother 2004; 48:2431–2436.
16.Fluit, AC, Verhoef, J, Schmitz, FJ. Antimicrobial resistance in European isolates of Pseudomonas aeruginosa. European Sentry Participants. Eur J Clin Microbiol Infect Dis 2000; 19:370–374.
17.National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 2003; 31:481–498.